Building the Next Generation of MedTech Leaders
Exploring One Six 8 Ventures’ Portfolio
One Six 8 Ventures focuses on funding next-generation MedTech companies through a precision-based approach designed to minimize risk and unlock superior returns. We target exceptional deals in Canada while identifying unique global opportunities that align with our investment thesis.
Our team leverages deep scientific experience and operational expertise to source opportunities from a pipeline of 600 annual deals, often partnering alongside institutional co-investors. This selective approach allows us to identify companies with strong technical foundations, clear paths to commercialization, and significant potential for strategic acquisition.
We seek entrepreneurs who are developing solutions that address urgent healthcare needs, demonstrate technological differentiation, and can scale to meet global demand. Our portfolio reflects this disciplined focus on companies positioned to become category leaders in their respective fields.
Current Portfolio Companies
-
Developing the world's first hybrid polymer-metal flow-diverting stent to provide a scaffold for enhanced vessel healing, effectively curing deadly brain aneurysms. Uniquely constructed of dissolving polymer and metal, this innovative medical device allows for superior post-operative visualization. This first-in-human validated technology is US patented and backed by top-tier clinical expertise to redefine neurovascular recovery and long-term patient outcomes.
-
Developing the world’s first non-invasive, image-guided laser platform to safely screen and treat eye floaters and other vitreoretinal diseases. By integrating next-generation femtosecond laser technology with machine learning-based tracking, PulseMedica is establishing a new standard of care for automated, office-based treatment. The company is backed by a global leader in eye care and leading venture partners to revolutionize retinal health through high-resolution 3D imaging and precise, automated intervention.
-
Providing a first-of-its-kind, end-to-end cardio-pulmonary platform for seamless remote care across the healthcare continuum. Respiree’s wearable sensors utilize proprietary AI to deliver real-time clinical monitoring and early intervention for hospital-at-home and chronic disease management. Backed by US FDA 510(k) clearance, CE approval, and TGA certification, the platform enables high-quality, enterprise-connected care from acute monitoring to rehabilitation.
-
Developing the world’s first AI-guided ultrasound platform for rapid Deep Vein Thrombosis diagnosis at the point of care. ThinkSono’s software integrates with handheld scanners, enabling non-specialist healthcare professionals to perform accurate scans in any clinical setting. Backed by FDA Breakthrough Device Designation and CE Mark, the platform streamlines diagnostic pathways while improving patient safety.
Our Unique MedTech Investment Approach
Our portfolio strategy centres on companies that demonstrate technical excellence, address substantial market opportunities, and maintain clear pathways to strategic value creation. We seek entrepreneurs who combine deep domain expertise with the ambition to build companies that transform healthcare delivery.
Through active partnership and strategic guidance, we work alongside our portfolio companies to accelerate development timelines, establish connections with strategic acquirers, and navigate the complex regulatory and commercial landscapes inherent to MedTech innovation. Our team's operational experience allows us to provide relevant support at each stage of company growth.
Partner with Experience
Meet our team to learn about the operators and executives guiding our portfolio companies, or get in touch to discuss potential investment opportunities.